Nesina, Kazano & Oseni Side Effects

Prescription drugs Nesina, Kazano and Oseni are Type 2 diabetes medications made by Takeda Pharmaceuticals America Inc. The most common side effects of all three medications are colds and upper respiratory infections. These drugs may not be right for everyone and may cause serious side effects. Oseni has a black box warning for the risk of heart failure, while Kazano has a black box warning for the risk of lactic acidosis.

Nesina, Kazano & Oseni pills
Nesina, Kazano & Oseni Side Effects Facts
  1. Common Side Effects Colds, headaches and upper respiratory tract infections
  2. Serious Side Effects Kidney conditions, pancreatitis
  3. Black Box Warning: Oseni Heart failure
  4. Black Box Warning: Kazano Lactic acidosis

Nesina, Kazano and Oseni are Type 2 diabetes drugs with active ingredients linked to serious side effects. These drugs belong to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. Takeda Pharmaceuticals America Inc. makes these drugs and refers to them as the Nesina family of medications because they all contain the main active ingredient alogliptin.

Kazano also contains metformin, and Oseni contains pioglitazone, which is also known as Actos. Doctors may prescribe these combination medications to some patients who need stronger blood sugar control. These drugs can cause the side effects of alogliptin and the side effects of metformin or pioglitazone.

Each additional ingredient may come with unique black box warnings and other serious side effects. For example, metformin has a black box warning for lactic acidosis and pioglitazone has a black box warning for congestive heart failure.

The U.S. Food and Drug Administration originally denied alogliptin’s drug approval in 2009 because it did not have sufficient cardiovascular data. After it approved the drug in 2013, the agency required Takeda to conduct additional studies. These postmarketing studies were intended to monitor liver abnormalities, pancreatitis and hypersensitivity reactions as well as the drug’s safety in children, according to ACP Diabetes Monthly.

Fact
Alogliptin’s most common side effects are common cold, headache and upper respiratory tract infection.

Nesina’s Common and Serious Side Effects

Researchers gathered data from 14,778 patients with Type 2 diabetes to conduct clinical trials, according to the Nesina medication insert. The average age of trial participants was 58 years old and they used the medication for 49 weeks. About 3,348 patients used the drug for more than a year. The trials allowed researchers to compile data about the most common side effects associated with the drug. In these trials, common side effects were those that occurred in 4 percent or more of trial participants.

According to the Nesina website, the most common side effects include:
  • Stuffy or runny nose and sore throat (4.8 percent)
  • Cold-like symptoms, upper respiratory tract infection (4.5 percent)
  • Headache (4.3 percent)

The majority of side effects found in clinical trials were not serious. But after the medication hit the market, the FDA and Takeda began receiving reports of previously unidentified adverse events.

From 2010 to Sept. 30, 2018, the FDA received 583 reports of Nesina side effects, according to the FDA Adverse Events Reporting System (FAERS) Public Dashboard. Of these reports, 461 cases were serious and included 53 deaths. Pemphigold accounted for the most reported cases, followed by acute pancreatitis and interstitial lung disease. People also reported gastrointestinal issues such as nausea.

Takeda’s Nesina website warns several side effects may be fatal or require hospitalization.

Alogliptin may cause the following serious side effects:
  • Acute pancreatitis
  • Heart failure
  • Hypersensitivity reactions
  • Liver injury
  • Hypoglycemia
  • Arthralgia (joint pain)
  • Bullous pemphigoid (skin condition marked by blisters and pain)

Acute Pancreatitis and Pancreatic Cancer

After taking medications containing alogliptin, people reported cases of acute pancreatitis, a condition where the pancreas becomes inflamed and swollen. In severe cases, this can lead to hospitalization and even death. Six patients treated with Nesina and two patients who took a placebo or other diabetes drug suffered pancreatitis in clinical trials, according to data in the drug’s insert.

The National Institutes of Health reports alogliptin has been “linked to rare instances of acute pancreatitis.”

A 2017 commentary by J. Hans DeVries and Julio Rosenstock in the journal Diabetes Care called the risk of pancreatitis from DDP-4 inhibitors “rare but real.” They pointed to “numerical imbalances” in previous clinical trials. They cited two new studies that showed a slight increase in the number of people who might develop pancreatitis after long-term alogliptin use.

Controversy still exists over whether DPP-4s can cause pancreatic cancer, and both the FDA and European Medicines Agency say not enough evidence exists to support this link.

In a study published in Diabetes in 2013, the researchers examined the pancreases of organ donors who were using DPP-4s and other incretin-based therapies. Researchers Alexandra Butler and colleagues found abnormal cells “with the potential for evolution into neuroendocrine tumors.”

Heart Failure

In 2016, the FDA required Takeda to add a warning for heart failure to all of its alogliptin-containing medications. The agency said the danger should be of particular concern for “patients who already have heart or kidney disease.”

In its safety communication, the agency said it looked at two large clinical trials that found 3.9 percent of alogliptin-treated patients were hospitalized for heart failure compared to 3.3 percent of patients who took a placebo.

Hypersensitivity Reactions

Postmarketing reports have shown serious hypersensitivity reactions in patients who take medications that contain alogliptin.

The drugs’ labels include warnings about the following reactions:
  • Anaphylaxis — a life-threatening, whole-body allergic reaction
  • Angioedema — swelling of the lower layer of skin and tissue just under the skin (mucous membranes)
  • Severe skin reactions — includes Stevens-Johnson syndrome, a potentially deadly skin disease that results from drug reactions

The labels instruct patients who have experienced angioedema with another DPP-4 inhibitor to use caution because it is unknown whether such patients may experience the same reaction with alogliptin. Patients who suspect a serious hypersensitivity reaction may need to stop taking the medication and consider alternative treatment for their diabetes, according to the label.

Liver Injury

Nesina’s medication insert says Takeda has received postmarketing reports of elevated liver enzymes, which may be a sign of liver injury. However, the company says the information is insufficient to determine the cause of liver injury.

The National Institutes of Health (NIH) says the FDA has received reports of liver failure and injury in patients who took alogliptin. But it says these reports are rare, and “the characteristics and details of the injury have not been defined in the published literature.” With other DPP-4s such as sitagliptin and saxagliptin, enzyme elevations typically happened within two to 12 weeks of starting treatment, NIH said.

Doctors may have some patients present with elevated liver enzymes or abnormal liver tests. If these persist or worsen, doctors should discontinue the drug if there is no other explanation for abnormal liver tests, the medication insert suggests.

Symptoms that may indicate injury or damage to the liver include fatigue, anorexia, right upper abdominal discomfort or pain, dark urine, or yellowing of the skin and whites of the eyes.

Joint Pain (Arthralgia)

In 2015, the FDA warned that drugs in the DPP-4 class may cause severe and disabling joint pain. The joint pain started in as little as one day to years after starting treatment. Typically, when the patient stopped the drug, the joint pain went away. But if they restarted treatment, the pain came back.

Out of all the drugs, alogliptin had the least number of reports of joint pain at the time of the safety communication. While Januvia had 28 reports, Nesina had only one.

Reports of Joint Pain
As of Sept. 20, 2018, FAERS had received six reports of arthralgia linked to Nesina.
Source: FDA Adverse Events Reporting System (FAERS) Public Dashboard

Kazano Side Effects and Black Box Warning

Kazano combines alogliptin with metformin. This means Kazano can cause all of the side effects of Nesina as well as those of metformin. From 2013 to Sept. 30, 2018, FAERS received 66 adverse event reports involving Kazano. These included 12 serious cases and one death.

In clinical trials, researchers tested alogliptin and metformin in 2,095 patients. According to the drug’s website, the most common side effects in trials included:
  • Cold-like symptoms or upper respiratory tract infection (8 percent)
  • Stuffy nose and sore throat (6.8 percent)
  • Diarrhea (5.5 percent)
  • Increased blood pressure (5.5 percent)
  • Headache (5.3 percent)
  • Back pain (4.3 percent)
  • Urinary tract infection (4.2 percent)

People who took alogliptin and metformin did not have any more side effects than those who took metformin alone in a 26-week trial period, according to the Canadian Agency for Drugs and Technologies in Health (CADTH). But, side effects increased during a 104-week study. Researchers noted that people who took a placebo suffered more reactions than those who took alogliptin with metformin.

Side Effects Specific to Metformin

Kazano carries a black-box warning for lactic acidosis, a potential side effect of metformin. Lactic acidosis is the buildup of lactic acid in the blood and requires immediate medical care. Without treatment, it can cause major organ failure.

Another potentially serious side effect of metformin is decreased B12 levels, according to Kazano’s medication label. Doctors should monitor their patients’ blood levels each year. B12 deficiency may lead to spinal cord disease and nerve and brain damage.

Did You Know
Metformin may result in ovulation and may lead to unintended pregnancies.
Common metformin side effects include:
  • Diarrhea
  • Nausea/vomiting
  • Flatulence
  • Weakness or lack of energy
  • Indigestion
  • Abdominal discomfort
  • Headache

Oseni Side Effects and Black Box Warning

Because Oseni is a combination of alogliptin and pioglitazone, it can cause all of the side effects of Nesina and the side effects of pioglitazone. Because it contains pioglitazone, Oseni carries a black box warning for congestive heart failure.

From 2013 to Sept. 30, 2018, FAERS received 175 postmarketing reports of adverse events involving people who took Oseni. The most reported adverse events were weight gain, edema and swelling.

Clinical trials for alogliptin coadministered with pioglitazone included safety data from more than 1,500 people, according to the drug’s medication insert. Common side effects occurred in 4 percent or more of trial participants.

According to Takeda’s website, the most common Oseni side effects include:
  • Stuffy or runny nose and sore throat (4.9 percent)
  • Back pain (4.2 percent)
  • Cold-like symptoms (4.1 percent)

Pioglitazone also increases the risk of edema and weight gain. In women, abnormal ovulation can occur, which can increase the possibility of pregnancy.

Germany, France and India removed Actos from the market after studies linked it to bladder cancer, but it remains on the market in the United States.

Urinary Bladder Tumors

A two-year laboratory study of Oseni’s potential to cause cancer showed tumors in the urinary bladders of male rats, according to the drug’s medication insert. Additionally, during a three-year randomized clinical trial called PROactive, 14 out of 2,605 participants who had taken pioglitazone and 5 out of 2,633 participants who had taken a placebo, developed bladder cancer. This shows an almost three times greater risk of bladder cancer in patients who take drugs that contain pioglitazone compared with those who have not taken the drugs.

Findings regarding the risk of bladder cancer in patients exposed to pioglitazone varied in subsequent observational studies, with some finding an increased risk of bladder cancer associated with the active ingredient and others finding no statistically significant increase.

One study published in 2016 in The BMJ concluded pioglitazone was associated with an increased risk of bladder cancer compared with other antidiabetic drugs. Researchers determined the side effect was specific to the drug, not necessarily the class.

“The results of this large population-based study indicate that pioglitazone is associated with an increased risk of bladder cancer,” the study’s authors wrote.

“The results of this large population-based study indicate that pioglitazone is associated with an increased risk of bladder cancer.”

Source: Pioglitazone Use and Risk of Bladder Cancer: Population Based Cohort Study

Fractures

Image that illustrates how bone fractures have been linked to patients’ use of pioglitazone.

The clinical trial PROactive linked incidences of bone fracture to patients’ use of pioglitazone, according to the Oseni drug label.

In the randomized study, 5.1 percent of female patients who had taken pioglitazone experienced bone fractures, while 2.5 percent of female participants who had been given a placebo experienced the same issue. Researchers noted bone fractures occurred after the first year of treatment and persisted throughout the course of the study.

Men treated with Oseni did not have a similar increase.

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for seven years. She specializes in fluoroquinolone antibiotics and products that affect women’s health such as Essure birth control, transvaginal mesh and talcum powder. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • American Medical Writers Association (AMWA) Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By
Medically Reviewed By
Dr. Joseph Palermo
Dr. Joseph Palermo Osteopathic Medicine

22 Cited Research Articles

  1. ACP Diabetes Monthly. (2013, May 10). Retrieved from https://diabetes.acponline.org/archives/2013/05/10/12.htm
  2. Appold, K. (2012). Dangers of Vitamin B12 Deficiency. Retrieved from http://www.todaysgeriatricmedicine.com/archive/012312p30.shtml
  3. Azoulay, L. et al. (2012, May 31). The Use of Pioglitazone and the Risk of Bladder Cancer in People with Type 2 Diabetes: Nested Case-Control Study. Retrieved from https://www.bmj.com/content/344/bmj.e3645.full.pdf+html
  4. Butler, A. et al. (2013, June 14). Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712065/
  5. Canadian Agency for Drugs and Technologies in Health. (2015). Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus [Internet]. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK349215/
  6. DailyMed. NIH. (2017, December 29). Label: Oseni – alogliptin and pioglitazone tablet, film coated. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55
  7. DailyMed. NIH. (2018, January 11). Label: Nesina – alogliptin tablet, film coated. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0
  8. DailyMed. NIH. (2018, November 13). Label: Kazano – alogliptin and metformin hydrochloride tablet, film coated. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2
  9. DeVries, J.H. and Rosenstock, J. (2017, February). DPP-4 Inhibitor-Related Pancreatitis: Rare but Real! Diabetes Care. Retrieved from http://care.diabetesjournals.org/content/diacare/40/2/161.full.pdf
  10. Dormandy, J. et al. (2009). Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19338377?dopt=Abstract
  11. Elashoff, M. et al. (2011, February 21). Pancreatitis, Pancreatic, and Thyroid Cancer with Glucagon-Like Peptide-1—Based Therapies. Retrieved from https://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract
  12. Filipova, E. et al. (2017, June 16). Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544610/
  13. National Institutes of Health. (2018, July 5). Drug Record; Alogliptin. Retrieved from https://livertox.nih.gov/Alogliptin.htm
  14. Scrica, B.M. et al. (2013, October 3). Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1307684
  15. Takeda Pharmaceuticals. (n.d.). Getting to Know the Nesina (alogliptin) Family — Learn About Type 2 Diabetes Options. Retrieved from https://www.nesinafamily.com/
  16. Tuccori, M. et al. (2016, March 30). Pioglitazone Use and Risk of Bladder Cancer: Population Based Cohort Study. The BMJ. Retrieved from https://www.bmj.com/content/352/bmj.i1541
  17. Tucker, M.E. & Barclay, L. (2013, February 28). FDA Approvals: Three New Type 2 Diabetes Formulations of Alogliptin. Retrieved from https://www.medscape.org/viewarticle/778318
  18. U.S. Food and Drug Administration. (2015, August 28). FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Retrieved from https://www.fda.gov/media/93280/download
  19. U.S. Food and Drug Administration. (2016, April 5). FDA Drug Safety Communication: FDA Adds Warnings About Heart Failure Risk to Labels of Type 2 Diabetes Medicines Containing Saxagliptin and Alogliptin. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes
  20. U.S. Food and Drug Administration. (n.d.). FDA Adverse Event Reporting System (FAERS) Public Dashboard. Retrieved from https://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
  21. White, W.B. et al. (2013, October 3). Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. The New England Journal of Medicine. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1305889
  22. Wilcox, R. et al. (2006, April). Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitazone Clinical Trial In macro Vascular Events (PROactive 10) American Heart Journal. Retrieved from https://www.sciencedirect.com/science/article/pii/S0002870307009842
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's sponsors support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617